Finance
Janux discontinues EGFR-targeted cancer therapy development
Janux discontinues EGFR-targeted cancer therapy development
I
Investing.com
April 27, 2026·1 min read
GM
FinanceJanux discontinues EGFR-targeted cancer therapy development
Original article
Janux discontinues EGFR-targeted cancer therapy development
Published by Investing.com